Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ALBT - Avalon GloboCare Corp.

IEX Last Trade
4.125
0   0%

Share volume: 102
Last Updated: Thu 26 Dec 2024 08:13:07 PM CET

PREVIOUS CLOSE
CHG
CHG%
$4.12
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Historical prices Events Documents Notes Dividends
Performance
5 Days
14.85%
1 Month
50.18%
3 Months
1,772.15%
6 Months
772.34%
1 Year
786.10%
2 Year
886.29%
Key data
Stock price
$4.12
P/E Ratio 
-0.26
DAY RANGE
$4.12 - $4.14
EPS 
-$1.35
52 WEEK RANGE
$0.19 - $6.55
52 WEEK CHANGE
$763.34
MARKET CAP 
3.929 M
YIELD 
N/A
SHARES OUTSTANDING 
15.984 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
-0.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$129,557
AVERAGE 30 VOLUME 
$2,583,303
Company detail
CEO: David K. Jin
Region: US
Website: http://www.avalon-globocare.com/
Employees: 5
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

Avalon GloboCare Corp. owns and operates commercial real estate properties in the United States and the People's Republic of China. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia. It is also developing RNA-based FASH-CARTM cell therapy platform.

Recent news